Last reviewed · How we verify
Placebo to vaniprevir
Vaniprevir is a protease inhibitor that targets the hepatitis C virus.
Vaniprevir is a protease inhibitor that targets the hepatitis C virus. Used for Chronic hepatitis C, Genotype 1 hepatitis C.
At a glance
| Generic name | Placebo to vaniprevir |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Protease inhibitor |
| Target | NS3/4A protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Vaniprevir works by binding to the NS3/4A protease of the hepatitis C virus, preventing the virus from replicating. This leads to a reduction in viral load and an improvement in liver function.
Approved indications
- Chronic hepatitis C
- Genotype 1 hepatitis C
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043) (PHASE3)
- A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016) (PHASE2)
- Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007) (PHASE2)
- Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009) (PHASE2)
- Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN) (PHASE2)
- Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to vaniprevir CI brief — competitive landscape report
- Placebo to vaniprevir updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI